NYSE: MAIA/Biotechnology
MAIA Biotechnology, Inc.
Chicago, IL, United States
Company overview
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
This profile is for informational purposes only and is not investment advice. Company information may change after the verification date.